Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus
dc.contributor.author | Güçlü, Metin | |
dc.contributor.author | Kıyıcı, Sinem | |
dc.contributor.buuauthor | Gül, Zülfiye | |
dc.contributor.buuauthor | Çavun, Sinan | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-8872-0074 | tr_TR |
dc.contributor.researcherid | AAF-9939-2020 | tr_TR |
dc.contributor.scopusid | 56086542900 | tr_TR |
dc.contributor.scopusid | 6507468595 | tr_TR |
dc.date.accessioned | 2024-01-18T05:22:30Z | |
dc.date.available | 2024-01-18T05:22:30Z | |
dc.date.issued | 2017-12-07 | |
dc.description.abstract | Aim: In the present study, we investigated the long-term effects of exenatide treatment on serum fasting ghrelin levels in patients with type 2 diabetes mellitus. Methods: Type 2 diabetic patients, who were using metformin with and without the other antihyperglycemic drugs on a stable dose for at least 3 months, were enrolled in the study. BMI>35 kg/m(2) and HbA1c>7.0% were the additional inclusion criteria. Oral antihyperglycemic drugs, other than metformin, were stopped, and metformin treatment was continued at 2000 mg per day. Exenatide treatment was initiated at 5 mu g per dose subcutaneously (sc) twice daily, and after one month, the dose of exenatide was increased to 10 mu g twice daily. Changes in anthropometric variables, glycemic control, lipid parameters and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment. Results: Thirty-eight patients (male/female = 7/31) entered the study. The mean age of patients was 50.5 +/- 8.8 years with a mean diabetes duration of 8.5 +/- 4.9 years. The mean BMI was 41.6 +/- 6.3 kg/m(2) and the mean HbA1c of patients was 8.9 +/- 1.4%. The mean change in the weight of patients was -5.6 kg and the percentage change in weight was -5.2 +/- 3.7% following 12 weeks of treatment. BMI, fasting plasma glucose and HbA1c levels of patients were decreased significantly (P < 0.001 and P < 0.001; respectively), while there was no change in lipid parameters. Serum fasting ghrelin levels were significantly suppressed following 12 weeks of exenatide treatment compared with baseline values (328.4 +/- 166.8 vs 245.3 +/- 164.8 pg/mL) (P = 0.024). Conclusion: These results suggest that the effects of exenatide on weight loss may be related with the suppression of serum fasting ghrelin levels, which is an orexigenic peptide. | en_US |
dc.identifier.citation | Güçlü, M. vd. (2018). ''Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus''. Endocrine Connections, 7(1), 193-198. | en_US |
dc.identifier.doi | https://doi.org/10.1530/EC-17-0242 | en_US |
dc.identifier.endpage | 198 | tr_TR |
dc.identifier.issn | 2049-3614 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 29217653 | tr_TR |
dc.identifier.scopus | 2-s2.0-85041344628 | tr_TR |
dc.identifier.startpage | 193 | tr_TR |
dc.identifier.uri | https://ec.bioscientifica.com/view/journals/ec/7/1/EC-17-0242.xml | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/39118 | en_US |
dc.identifier.volume | 7 | tr_TR |
dc.identifier.wos | 000426045300026 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Bioscientifica Ltd | en_US |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Endocrine Connections | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Endocrinology & metabolism | en_US |
dc.subject | Exenatide | en_US |
dc.subject | Ghrelin | en_US |
dc.subject | Diabetes | en_US |
dc.subject | Glycemic control | en_US |
dc.subject | Insulin | en_US |
dc.subject | Weight | en_US |
dc.subject | Exendin-4 | en_US |
dc.subject | Metformin | en_US |
dc.subject | Peptide | en_US |
dc.subject | Glp-1 | en_US |
dc.subject | Cell | en_US |
dc.subject.emtree | Alanine aminotransferase | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Exendin 4 | en_US |
dc.subject.emtree | Ghrelin | en_US |
dc.subject.emtree | Hemoglobin A1c | en_US |
dc.subject.emtree | High density lipoprotein cholesterol | en_US |
dc.subject.emtree | Low density lipoprotein cholesterol | en_US |
dc.subject.emtree | Metformin | en_US |
dc.subject.emtree | Triacylglycerol | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Body mass | en_US |
dc.subject.emtree | Body weight | en_US |
dc.subject.emtree | Body weight loss | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Diastolic blood pressure | en_US |
dc.subject.emtree | Drug dose increase | en_US |
dc.subject.emtree | Drug withdrawal | en_US |
dc.subject.emtree | Enzyme linked immunosorbent assay | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Glycemic control | en_US |
dc.subject.emtree | High performance liquid chromatography | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Longitudinal study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Non insulin dependent diabetes mellitus | en_US |
dc.subject.emtree | Obesity | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Systolic blood pressure | en_US |
dc.subject.scopus | Ghrelin Receptors; Acyltransferases; Eating | en_US |
dc.subject.wos | Endocrinology & metabolism | en_US |
dc.title | Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q3 (Endocrinology & metabolism) | en_US |